Biofrontera Inc
BFRIW0.051USD
-0.009-14.50%
Close 01/16, 16:00（ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Biofrontera Inc Company
Biofrontera Inc. is a biopharmaceutical company. The Company is focused on commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its principal licensed product is Ameluz, which is a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy. In the United States, the PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses (AK) of mild-to-moderate severity on the face and scalp. Its second prescription drug licensed product in its portfolio is Xepi, which is a topical non-fluorinated quinolone that inhibits bacterial growth and used for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes.
Biofrontera Inc Info
Ticker SymbolBFRIW
Company nameBiofrontera Inc
IPO dateOct 14, 2021
CEOProf. Dr. Hermann Luebbert, Ph.D.
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
Address120 Presidential Way,
CityWOBURN
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code01801
Phone17812451325
Websitehttps://www.biofrontera-us.com/
Ticker SymbolBFRIW
IPO dateOct 14, 2021
CEOProf. Dr. Hermann Luebbert, Ph.D.
Company Executives of Biofrontera Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Beth J. Hoffman, Ph.D.
Dr. Beth J. Hoffman, Ph.D.
Independent Director
Independent Director
--
--
Prof. Dr. Hermann Luebbert, Ph.D.
Prof. Dr. Hermann Luebbert, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Eugene Frederick (Fred) Leffler, III
Mr. Eugene Frederick (Fred) Leffler, III
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Heikki Lanckriet, Ph.D.
Dr. Heikki Lanckriet, Ph.D.
Director
Director
--
--
Dr. John J. Borer, III
Dr. John J. Borer, III
Independent Director
Independent Director
--
--
Mr. Kevin D. Weber
Mr. Kevin D. Weber
Independent Director
Independent Director
--
--
Mr. George Jones
Mr. George Jones
Chief Commercial Officer
Chief Commercial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Beth J. Hoffman, Ph.D.
Dr. Beth J. Hoffman, Ph.D.
Independent Director
Independent Director
--
--
Prof. Dr. Hermann Luebbert, Ph.D.
Prof. Dr. Hermann Luebbert, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Eugene Frederick (Fred) Leffler, III
Mr. Eugene Frederick (Fred) Leffler, III
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Heikki Lanckriet, Ph.D.
Dr. Heikki Lanckriet, Ph.D.
Director
Director
--
--
Dr. John J. Borer, III
Dr. John J. Borer, III
Independent Director
Independent Director
--
--
Mr. Kevin D. Weber
Mr. Kevin D. Weber
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
10
221.07K
0.00%
+20.09K
2025Q3
10
221.07K
0.00%
+32.90K
2025Q2
9
188.18K
0.00%
-14.39K
2025Q1
9
202.57K
0.00%
-20.78K
2024Q4
8
194.67K
0.00%
-4.54K
2024Q3
8
199.21K
0.00%
-5.10K
2024Q2
10
279.32K
0.00%
-22.61K
2024Q1
10
301.92K
0.00%
-5.11K
2023Q4
9
293.58K
0.00%
-7.33K
2023Q3
10
302.16K
0.00%
-94.14K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Two Sigma Investments, LP
--
0%
-10.14K
-100.00%
Sep 30, 2025
Bard Associates Inc.
154.90K
0%
--
--
Sep 30, 2025
Clear Street LLC
9.24K
0%
-200.00
-2.12%
Jun 30, 2025
UBS Financial Services, Inc.
--
0%
-891.00
-100.00%
Jun 30, 2025
Osaic Holdings, Inc.
1.10K
0%
--
--
Sep 30, 2025
Clear Street Group Inc
8.94K
0%
+8.94K
--
Sep 30, 2025
U.S. Bancorp Asset Management, Inc.
1.00K
0%
--
--
Sep 30, 2025
Susquehanna International Group, LLP
45.89K
0%
+34.09K
+288.91%
Sep 30, 2025
Citadel Advisors LLC
--
0%
-11.62K
-100.00%
Sep 30, 2024
BofA Global Research (US)
--
0%
-100.00
-100.00%
Dec 31, 2024
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Biofrontera Inc?
The top five shareholders of Biofrontera Inc are:
Two Sigma Investments, LP holds 0.00 shares, accounting for 0.00% of the total shares.
Bard Associates Inc. holds 154.90K shares, accounting for 0.00% of the total shares.
Clear Street LLC holds 9.24K shares, accounting for 0.00% of the total shares.
UBS Financial Services, Inc. holds 0.00 shares, accounting for 0.00% of the total shares.
Osaic Holdings, Inc. holds 1.10K shares, accounting for 0.00% of the total shares.
Two Sigma Investments, LP holds 0.00 shares, accounting for 0.00% of the total shares.
Bard Associates Inc. holds 154.90K shares, accounting for 0.00% of the total shares.
Clear Street LLC holds 9.24K shares, accounting for 0.00% of the total shares.
UBS Financial Services, Inc. holds 0.00 shares, accounting for 0.00% of the total shares.
Osaic Holdings, Inc. holds 1.10K shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of Biofrontera Inc?
The top three shareholder types of Biofrontera Inc are:
Other
Other
How many institutions hold shares of Biofrontera Inc (BFRIW)?
As of 2025Q4, 10 institutions hold shares of Biofrontera Inc, with a combined market value of approximately 221.07K, accounting for --% of the total shares. Compared to 2025Q3, institutional shareholding has increased by --.
What is the biggest source of revenue for Biofrontera Inc?
In --, the -- business generated the highest revenue for Biofrontera Inc, amounting to -- and accounting for --% of total revenue.
